Get started
Award

U01 HL123336

Funded outputs count: 70
Funder award ID: U01 HL123336
OpenAlex ID: G890154010
Primary Prevention for People Living With HIV
2026 · Markella V. Zanni, Michael T. Lu, et al. · Journal of the American College of Cardiology
Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis
2026 · Triin Umbleja, Mohammad U Zafar, et al. · The Lancet HIV · 2
PDF
Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
2025 · Gerald S. Bloomfield, Maya Watanabe, et al. · Circulation Heart Failure · 3
Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV
2025 · Márton Kolossváry, Irini Sereti, et al. · Journal of Clinical Investigation · 5
PDF
No evidence of pitavastatin effect on muscle area or density among people with HIV
2025 · Kristine M. Erlandson, Triin Umbleja, et al. · AIDS · 3
No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIV
2025 · Kristine M. Erlandson, Ashley McKhann, et al. · AIDS · 6
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis
2025 · Carl J Fichtenbaum, Carl J Fichtenbaum, et al. · The Lancet HIV · 12
Prognostic Factors of Physical Function Decline Among Middle-Aged Adults With HIV
2025 · Grace L Kulik, Triin Umbleja, et al. · Open Forum Infectious Diseases · 2
PDF
Risks for sudden cardiac and undetermined cause of death among people with HIV in the REPRIEVE primary cardiovascular prevention trial
2025 · Christopher deFilippi, Aya Awwad, et al. · AIDS · 3
PDF
Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE Substudy
2025 · Michael T. Lu, Heather J. Ribaudo, et al. · JACC Advances · 9
Factors Affecting Risk of Cardiovascular Disease (CVD) Events in a Global CVD Prevention Cohort of People With HIV
2025 · Steven K Grinspoon, Maya Watanabe, et al. · Clinical Infectious Diseases · 8
PDF
Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trial
2025 · Marissa R Diggs, Triin Umbleja, et al. · The Lancet HIV · 4
Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort
2025 · Emma Davies Smith, Carlos Malvestutto, et al. · Open Forum Infectious Diseases · 13
Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE
2025 · Steven K Grinspoon, Markella V Zanni, et al. · The Lancet HIV · 36
A novel biomarker to identify atherosclerotic cardiovascular disease in people with HIV and assessment of clinical and ECG features associated with incident sudden cardiac or undetermined death: Insights from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
2025 · deFilippi, Christopher Roy · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
PDF
Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV
2024 · Márton Kolossváry, Samuel R. Schnittman, et al. · JAMA Cardiology · 16
Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention
2024 · Kathleen V. Fitch, Markella V. Zanni, et al. · Annals of Internal Medicine · 9
PDF
Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIV
2024 · Markella V Zanni, Triin Umbleja, et al. · Open Forum Infectious Diseases · 2
Proteinuria and albuminuria among a global primary cardiovascular disease prevention cohort of people with HIV
2024 · Edgar T. Overton, Amy Kantor, et al. · AIDS · 5
PDF
What have we learned from the REPRIEVE trial and where do we go from here?
2024 · Steven K. Grinspoon, Michael T. Lu, et al. · HIV Medicine · 3
PDF
Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function
2024 · Kristine M Erlandson, Triin Umbleja, et al. · Clinical Infectious Diseases · 6
PDF
Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIV
2024 · Christopher deFilippi, Sara McCallum, et al. · JACC Advances · 7
Coronary Plaque in People With HIV vs Non-HIV Asymptomatic Community and Symptomatic Higher-Risk Populations
2024 · Julia Karady, Michael T. Lu, et al. · JACC Advances · 13
Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection
2024 · Steven K. Grinspoon, Heather J. Ribaudo, et al. · New England Journal of Medicine · 45
PDF
Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial
2024 · Romit Bhattacharya, Md Mesbah Uddin, et al. · Blood Advances · 11
PDF
Year
Topic